AltimmuneAltimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801), chronic hepatitis B (HepTcell™), and conjugated immunostimulants for the treatment of cancer (ALT-702). In addition, we are developing intranasal vaccine & therapeutic candidates for influenza (NasoVAX™), anthrax (NasoShield™) and COVID-19 (AdCOVID and T-COVID). For more information please visit www.altimmune.com.
